Navigation Links
Liverpool receives $1.5M to tackle disease in Africa
Date:1/13/2011

A University of Liverpool-led consortium has received $1.5million from the Bill & Melinda Gates Foundation to study a bacterium that causes serious disease and epidemics in sub-Saharan Africa.

Streptococcus pneumoniae serotype1 is one of the most prevalent strains in sub-Sahara Africa. The funding will enable scientists to analyse the bacterium to determine why it is associated with invasive pneumococcal disease, why it spreads so quickly and why it has significant epidemic potential in some areas of Africa.

Invasive pneumococcal disease causes life-threatening pneumonia, meningitis and sepsis and is a major cause of death and serious illness in Africa. There are more than 90 different serotypes of Streptococcus pneumoniae - the bacterium that causes pneumococcal disease - but only a small number are associated with invasive pneumococcal disease.

Researchers based in Malawi, Nigeria, South Africa and The Gambia will analyse 300 wide-ranging and geographically relevant strains of Streptococcus pneumoniae serotype 1 to provide a detailed study of its genetic traits. The data will contribute to the current pneumococcal vaccine development programme led by PATH in the USA. In the longer term, the information will feed into the development of a protein-based vaccine that will enhance or replace current Pneumococcal Conjugate Vaccines (PCVs).

Vaccination provides the best form of protection against invasive pneumococcal disease. However, the vaccination programme that is being rolled out across Africa may not provide adequate protection against serotype 1. There are a number of PCVs currently available but none have shown a strong protective effect against serotype 1 and it is not known yet how the proposed PCVs which are due to be introduced to the programme will fare.

The project will also involve African researchers being trained to undertake the genomic-based research to enable local African researchers to process and analyse relevant data.

Dr Dean Everett, who is based in Malawi working as part of the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, said: "Streptococcus pneumoniae serotype 1 is one of the biggest causes of pneumococcal disease in sub-Sahara Africa and accounts for a quarter of infections in Malawi."

"Understanding the genetic traits that underpin serotype 1 and contribute towards its epidemic potential will help us to refine vaccine target discovery and guide the vaccine development process in order to provide better protection to those in sub-Saharan Africa where this serotype is most prevalent. This is an important first step in the process and importantly it will be driven by researchers in Africa."

Partners organisation involved in the consortium include: the University of Liverpool; the Malawi College of Medicine; Centre de Recherche Medicale et Sanitaire, Niger; National Health Laboratory Service, South Africa; Medical Research Council, The Gambia; the Wellcome Trust; the Liverpool School of Tropical Medicine; the London School of Tropical Medicine and Emory University in the USA.


'/>"/>

Contact: Sarah Stamper
sarah.stamper@liv.ac.uk
01-517-943-044
University of Liverpool
Source:Eurekalert

Related medicine news :

1. Case Western Reserve receives $10M to study retinal disease, develop new treatments
2. University of Houston receives $5 million grant from Houston Endowment
3. BMC radiologist receives 2010 Marie Sklodowska-Curie Award from AAWR
4. Dartmouth receives $2 million grant for childrens health research center
5. Harvard expert on inflammations role in obesity receives Columbias 2010 Naomi Berrie Award
6. Earl Smith receives Prentice Medal from American Academy of Optometry
7. Fred Hutchinson Cancer Research Center scientist receives Presidential Early Career Award
8. Miriam receives $1.5 million from NIH to seek, test and treat inmates with HIV
9. National Jewish Health receives patent for diagnostic method of autoimmune chronic urticaria
10. Breast center receives RI Pink Heals donation
11. UC San Diego receives 2 major biomedical informatics grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
(Date:3/27/2017)... ... , ... Buzzies parent company, The TouchPoint Solution’s CEO and co-founder, Vicki Mayo, ... Project Entrepreneur. Mayo will present her pitch about the lifestyle wearable devices, Buzzies ... venture competition ignites bold ideas by providing women access to the tools, training and ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, the leading multimedia ... medicine, announces the launch of Veterinarian’s Money Digest™, a business and financial resource ... of American Veterinarian™. , “We look forward to launching Veterinarian’s Money ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... ... , ... According to the American Cancer Society , the average 15-year ... Once the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year ... this latter group, tune in to Lifestyle Magazine on April 9, 2017, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced ... M. Bisaro as Impax,s President and Chief Executive ... March 27, 2017. Mr. Bisaro will succeed J. ... and Chief Executive Officer since December of 2016. ... pharmaceutical experience, Mr. Bisaro, 56, is an accomplished global ...
(Date:3/27/2017)... AUSTIN, Texas , March 27, 2017   Genprex, Inc. ... announced that Julien Pham , MD, the Company,s Chief Operating ... healthcare investor conferences. Sachs 5th Annual Cancer BioPartnering ... in New York, NY ... BioCentury 24th Annual Future Leaders ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 ... "Cell Therapy Manufacturing Market, 2017-2027" report to their offering. ... The ... of the rapidly growing market of cell therapy manufacturing and ... in-house manufacturing facilities. These therapies are anticipated to emerge as ...
Breaking Medicine Technology: